Palatin Technologies Inc (PTN) — SEC Filings
Palatin Technologies Inc (PTN) — 41 SEC filings. Latest: 8-K/A (Dec 19, 2025). Includes 22 8-K, 6 10-Q, 4 S-1/A.
View Palatin Technologies Inc on SEC EDGAR
Overview
Palatin Technologies Inc (PTN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K/A filed on Dec 19, 2025: Palatin Technologies, Inc. filed an 8-K/A on December 19, 2025, to amend a previous filing regarding the submission of matters to a vote of security holders. The original event date was July 25, 2025. The company is incorporated in Delaware and its principal executive offices are located in Princeto
Sentiment Summary
Across 41 filings, the sentiment breakdown is: 1 bullish, 9 bearish, 30 neutral, 1 mixed. The dominant filing sentiment for Palatin Technologies Inc is neutral.
Filing Type Overview
Palatin Technologies Inc (PTN) has filed 2 8-K/A, 6 10-Q, 22 8-K, 4 S-1/A, 2 10-K, 2 DEF 14A, 2 S-1, 1 SC 13G/A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (41)
Risk Profile
Risk Assessment: Of PTN's 38 recent filings, 7 were flagged as high-risk, 18 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $8,847,550 |
| Net Income | $4,677,534 |
| EPS | $4.81 |
| Debt-to-Equity | N/A |
| Cash Position | $1,273,083 |
| Operating Margin | 52.5% |
| Total Assets | $8,614,660 |
| Total Debt | $8,218,261 |
Key Executives
- Stephen T. Wills
- Faith L. Charles, Esq.
- Carl Spana
- Stephen A. Slusher, Esq.
Industry Context
Palatin Technologies operates in the biopharmaceutical sector, focusing on developing first-in-class medicines targeting the melanocortin receptor system. This highly competitive industry requires significant R&D investment and faces long development timelines and stringent regulatory hurdles. Key areas of focus include obesity, metabolic disorders, and inflammatory diseases, where unmet medical needs present significant market opportunities.
Top Tags
material-agreement (6) · financials (5) · 10-Q (5) · corporate-governance (4) · Pharmaceuticals (4) · sec-filing (4) · 8-k (4) · amendment (3) · Biotechnology (3) · Clinical Trials (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $4.68M | Swung from a $7.82M loss in Q3 2024 to a $4.68M profit in Q3 2025, driven by collaboration revenue. |
| Collaboration and License Revenue | $8.85M | Generated $8.85M in Q3 2025, up from $0 in Q3 2024, a key driver of profitability. |
| Cash and Cash Equivalents | $1.27M | As of September 30, 2025, but significantly bolstered by $22.3M in post-quarter funding. |
| Research and Development Expenses | $2.53M | Decreased by 56% from $5.74M in Q3 2024 to $2.53M in Q3 2025. |
| Accumulated Deficit | $454.40M | Reduced from $459.07M at June 30, 2025, but still represents significant historical losses. |
| Reverse Stock Split | 1-for-50 | Effective August 11, 2025, impacting share count and per-share metrics. |
| Common Shares Outstanding | 1,702,675 | As of November 12, 2025, post-reverse split and public offering. |
| Basic Net Income Per Common Share | $4.81 | A significant improvement from a basic net loss of $(19.71) per share in Q3 2024. |
| Shares of Common Stock offered | 2,307,692 | Maximum number of shares in the public offering |
| Assumed combined public offering price | $6.50 | Midpoint price per share of Common Stock and accompanying Common Warrants |
| Exercise price of Pre-Funded Warrants | $0.0001 | Nominal exercise price for Pre-Funded Warrants |
| Underwriting discounts and commissions | 7.0% | Cash fee percentage of aggregate purchase price |
| Underwriter Warrants percentage | 2% | Percentage of shares sold in offering granted as warrants to underwriters |
| Over-allotment option shares | 346,153 | Additional shares A.G.P. can purchase (15% of offering) |
| Last reported sale price on OTCQB | $7.10 | Price per share on October 16, 2025, prior to the offering |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Palatin Technologies Inc (PTN)?
Palatin Technologies Inc has 41 recent SEC filings from Feb 2024 to Dec 2025, including 22 8-K, 6 10-Q, 4 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PTN filings?
Across 41 filings, the sentiment breakdown is: 1 bullish, 9 bearish, 30 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Palatin Technologies Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Palatin Technologies Inc (PTN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Palatin Technologies Inc?
Key financial highlights from Palatin Technologies Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PTN?
The investment thesis for PTN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Palatin Technologies Inc?
Key executives identified across Palatin Technologies Inc's filings include Stephen T. Wills, Faith L. Charles, Esq., Carl Spana, Stephen A. Slusher, Esq..
What are the main risk factors for Palatin Technologies Inc stock?
Of PTN's 38 assessed filings, 7 were flagged high-risk, 18 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Palatin Technologies Inc?
Forward guidance and predictions for Palatin Technologies Inc are extracted from SEC filings as they are enriched.